

Name of Journal: *World Journal of Clinical Oncology*

Manuscript NO: 59435

Manuscript Type: EDITORIAL

Nonmetastatic castration-resistant prostate cancer: Novel agents to treat a lethal disease

Ivan Henriquez, Daniel Spratt, Alfonso Gómez-Iturriaga, Oscar Abuchaibe, Felipe Couñago

Abstract

Nonmetastatic castration-resistant prostate cancer (nmCRPC) - defined as prostate-specific antigen (PSA) > 2 ng/mL, testosterone castration levels < 1.7 nm/L, and the absence of metastatic lesions on conventional imaging (computed tomography or bone scan) - has been defined as a lethal disease by the Prostate Cancer Work Group. One-

Match Overview

1	Internet 28 words crawled on 07-Oct-2020 pubmed.ncbi.nlm.nih.gov	1%
2	Internet 26 words crawled on 17-Jul-2020 www.mdpi.com	1%

Nonmetastatic Castration-Resistant Prostate Cancer: Novel Agents to Tre

ALL IMAGES VIDEOS

64,400 Results Any time

Managing Nonmetastatic Castration-resistant Prostate Cancer

<https://pubmed.ncbi.nlm.nih.gov/30119985>

Context: Patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) have rising prostate-specific antigen (PSA) and castrate testosterone levels, with no radiological findings of metastatic disease on computed tomography and bone scan. Given recent drug approvals for nmCRPC, with many other therapeutics and imaging modalities being developed, management of nmCRPC is a ...

Cited by: 56 Author: Joaquin Mateo, Karim Fizazi, Silke Gilles...
Publish Year: 2019

Novel Drug Improves Survival in Advanced Prostate Cancer

<https://news.feinberg.northwestern.edu/2020/07/novel-drug-improves-survival-in...>

Jul 10, 2020 · Novel Drug Improves Survival in Advanced Prostate Cancer. Maha Hussain, MBChB, the Genevieve E. Teuton Professor of Medicine in the Division of Hematology and Oncology, was the senior author of the study published in The New England Journal of Medicine. A novel drug called enzalutamide may extend overall survival for men with nonmetastatic castration-resistant prostate cancer.

Prostate Cancer

Medical Condition

Changes in urination, painful ejaculation and erectile dysfunction




A cancer of the prostate gland, a part of the male reproductive system.

Very common (More than 3 million cases)

Nonmetastatic castration-resistant prostate cancer: Novel agents to



ALL

IMAGES

VIDEOS

61,500 Results

Any time ▾

[Managing Nonmetastatic Castration-resistant Prostate Cancer](https://pubmed.ncbi.nlm.nih.gov/30119985)

<https://pubmed.ncbi.nlm.nih.gov/30119985>

Context: Patients with **nonmetastatic castration-resistant prostate cancer (nmCRPC)** have rising **prostate-specific antigen (PSA)** and **castrate testosterone** levels, with no radiological findings of metastatic disease on computed tomography and bone scan. Given recent **drug approvals** for nmCRPC, with many other therapeutics and imaging modalities being developed, management of nmCRPC is a ...

Cited by: 55

Author: Joaquin Mateo, Karim Fizazi, Silke Gillese...

Publish Year: 2019

[Management of Nonmetastatic Castration-Resistant Prostate ...](https://pubmed.ncbi.nlm.nih.gov/30741354)

<https://pubmed.ncbi.nlm.nih.gov/30741354>

Abstract. Nonmetastatic castration-resistant prostate cancer (nmCRPC) comprises a relatively narrow niche of advanced prostate cancer, but the treatment landscape for men with **nmCRPC** has drastically changed over the past year. Prior to the SPARTAN and PROSPER trials, men with **nmCRPC** were commonly treated with **first-generation androgen receptor antagonists**, such as **bicalutamide** or **flutamide**, or with **estrogens** or **ketoconazole**...

Cited by: 4

Author: John Esther, Benjamin L Maughan, Neysi A...

Publish Year: 2019

[Novel Androgen Receptor Signaling ... - Cancer Network](https://www.cancernetwork.com/view/novel-androgen...)

<https://www.cancernetwork.com/view/novel-androgen...>

Often, as Luo et al review in this issue of ONCOLOGY, [1] management of **nonmetastatic CRPC** involves either a waiting game or treatment with agents that have modest activity with acceptable tolerability (eg, first-generation antiandrogens). However, hope is on the horizon in the form of **novel androgen receptor signaling inhibitors (ARSIs)**.

[Treatment of non-metastatic castration resistant prostate ...](https://www.sciencedirect.com/science/article/pii/S1078143919304806)

<https://www.sciencedirect.com/science/article/pii/S1078143919304806>

Apr 01, 2020 · Abstract. Lately the development of 3 **novel second-generation androgen receptor antagonists (enzalutamide, apalutamide, and darolutamide)** changed the treatment landscape of nonmetastatic castration-resistant prostate cancer. After proofing their clinical efficacy in large phase III registration trials with good compatibilities and tolerable side effects currently all 3 substances are Food and Drug Administration-approved ...

Cited by: 1

Author: Isobel Heidgger, Maximilian B Brandt, Met

Prostate Cancer

Medical Condition

A cancer of the prostate gland, a part of the male reproductive system.

Very common (More than 3 million cases per year in US)

Often requires lab test or imaging

Treatment from medical professional advised

Can last several years or be lifelong

Prostate gland is a part of the male reproductive system that helps in semen production. Prostate cancer develops when the prostate cells undergo genetic changes. Changes in urination, painful ejaculation, and erectile dysfunction are the main symptoms. Treatments include chemotherapy, medications to stop hormone activity, radiation therapy, and surgery. These can be used alone or in combinations to treat cancer.

Symptoms

Early stage prostate cancer may not cause any signs or symptoms. Symptoms commonly noted during the advanced stage include:

- Trouble urinating
- Frequent urination
- Decreased force of urination
- Difficulty starting or stopping urine stream
- Blood in semen
- Pain or discomfort in the pelvic area
- Bone pain

Treatments

The choice of treatment is based on type and stage of cancer, and the overall health of the patient. Low-risk prostate cancer may not need immediate treatment, but regular follow-up is advised.

Medication

- Hormone therapy - Luteinizing hormone-releasing hormone (LH-RH)



ALL

IMAGES

VIDEOS

MAPS

NEWS

SHOPPING

61,600 Results

Any time ▾

[Management of Nonmetastatic Castration-Resistant Prostate ...](#)

<https://pubmed.ncbi.nlm.nih.gov/30741354>

Abstract. Nonmetastatic castration-resistant prostate cancer (nmCRPC) comprises a relatively narrow niche of advanced prostate cancer, but the treatment landscape for men with **nmCRPC** has drastically changed over the past year. Prior to the SPARTAN and PROSPER trials, men with **nmCRPC** were commonly treated with **first-generation androgen receptor antagonists**, such as **bicalutamide** or **flutamide**, or with **estrogens** or **ketoconazole**...

Cited by: 4

Author: John Esther, Benjamin L Maughan, Neysi A...

Publish Year: 2019

[Treatment of non-metastatic castration resistant prostate ...](#)

<https://www.sciencedirect.com/science/article/pii/S1078143919304806>

Apr 01, 2020 · The recent development of three **novel second-generation AR antagonists** (**enzalutamide**, **apalutamide**, **darolutamide**) changed the **treatment** landscape for **non metastatic castration resistant prostate cancer**.

Cited by: 1

Author: Isabel Heidegger, Maximilian P. Brandt, Mat...

Publish Year: 2020

[Managing Nonmetastatic Castration-resistant Prostate Cancer](#)

<https://pubmed.ncbi.nlm.nih.gov/30119985>

Context: **Patients** with **nonmetastatic castration-resistant prostate cancer (nmCRPC)** have rising **prostate-specific antigen (PSA)** and **castrate testosterone** levels, with no radiological findings of metastatic disease on computed tomography and bone scan. Given recent **drug approvals** for nmCRPC, with many other therapeutics and imaging modalities being developed, management of nmCRPC is a ...

Cited by: 55

Author: Joaquin Mateo, Karim Fizazi, Silke Gillesse...

Publish Year: 2019

[Novel Therapies for Metastatic Castrate-Resistant Prostate ...](#)